Tafinlar (dabrafenib) — Medica
Hairy Cell Leukemia
Initial criteria
- Patient has not been previously treated with a BRAF inhibitor therapy
- Medication will be used for relapsed/refractory disease
- Medication will be taken in combination with Mekinist (trametinib tablets and oral solution)
Approval duration
1 year